Exelixis Inc. (EXEL) Plunges 7.95% on August 03

Equities Staff  |

Exelixis Inc. (EXEL) had a rough trading day for Friday August 03 as shares tumbled 7.95%, or a loss of $-1.78 per share, to close at $20.62. After opening the day at $22.53, shares of Exelixis Inc. traded as high as $22.62 and as low as $20.53. Volume was 6.37 million shares over 33,826 trades, against an average daily volume of 4.31 million shares and a total float of 298.04 million.

As a result of the decline, Exelixis Inc. now has a market cap of $6.15 billion.

The stock has a P/E Ratio of 21.7.

In the last year, shares of Exelixis Inc. have traded between a range of $32.50 and $18.50, and its 50-day SMA is currently $20.72 and 200-day SMA is $24.51.

For a complete fundamental analysis of Exelixis Inc., check out Equities.com’s Stock Valuation Analysis report for EXEL.

Still paying commissions on stock trades? Equities.com now offers 100% commission free stock trading and flat-fee options trading for $89.95/month! Get started today by https://www.equities.com/trading

Exelixis Inc is a biotechnology company. It is involved in discovery, development, and commercialization of new medicines for people with cancer. The Cabometyx product generates maximum revenue for the company.

Exelixis Inc. is based out of South San Francisco, CA and has some 372 employees. Its CEO is Michael M. Morrissey.

Exelixis Inc. is a component of the Russell 2000. The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

To get more information on Exelixis Inc. and to follow the company’s latest updates, you can visit the company’s profile page here: EXEL’s Profile. For more news on the financial markets and emerging growth companies, be sure to visit Equities.com’s Newsdesk. Also, don’t forget to sign-up for our daily email newsletter to ensure you don’t miss out on any of our best stories.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer



Symbol Last Price Change % Change